Iben Spanggaard

7PUBLICATIONS
53CO-AUTHORS
Solid tumoursCancer geneticsPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 26, 2026
A Phase Ib/II Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden.

|Apr 15, 2025
Treating intrahepatic cholangiocarcinoma with pemigatinib: two case reports of Nordic patients.

Vesa T Väliaho, Iben Spanggaard

|Mar 13, 2025
Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors.

Martina Eriksen, Anne M Hansen, Annelaura B Nielsen

|May 06, 2024
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

Jordi Rodón, Silvia Damian, Muhammad Furqan

|May 10, 2023
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors.

Ignacio Melero, Tamara Tanos, Mariana Bustamante

|Feb 06, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

James J Harding, Sarina A Piha-Paul, Ronak H Shah

Pageof 2

Frequent Collaborators

3 joint publications

Kristoffer S Rohrberg

2 joint publications

Jesús García-Donas

2 joint publications

Antoine Italiano

2 joint publications

Victor Moreno